The aim of this study was (1) to determine whether the EGFR mutations in tumour tissue and serum samples from advanced NSCLC patients are the same, and (2) to identify whether there is a correlation between EGFR mutation status detected in serum DNA and both response to gefitinib and survival benefit from gefitinib. The gene discussed is EGFR; the disease is neoplasm.